There's no doubt about the inflammation treatment product that has been working with additional breakthrough achievements.
The November submit could improve Msb's marketing strategy in order to lure more investments and investors.
The lungs failure will lead to heart failure in the Covid patients and I still don't understand why the FDA did not do anything to help Msb to launch its products.
The media will change ones belief. I'm back for good stuffs to come.
Ann: CHF Late Breaker Presentation at American Heart Association, page-25
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.030(2.71%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.14 | $1.08 | $2.811M | 2.541M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 59385 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 88912 | 7 |
View Market Depth
| Last trade - 14.31pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |